Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.3500 (3.68%) ($5.0700 - $5.4500) on Thu. Oct. 3, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.51% (three month average) | RSI | 26 | Latest Price | $5.3500(3.68%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | TGTX declines -8.7% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.755% in a week (0% probabilities). VIXM(-39%) VXX(-37%) TLT(-8%) UUP(-7%) IGOV(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.755% (StdDev 3.51%) | Hourly BBV | 0 () | Intraday Trend | 3.5% | | | |
|
1 - 5 Day Possible Target | $-11.4(-313.08%) | Resistance Level | $6.06 | 5 Day Moving Average | $5.4(-0.93%) | 10 Day Moving Average | $5.58(-4.12%) | 20 Day Moving Average | $6.06(-11.72%) | To recent high | -40.5% | To recent low | 3.7% | Market Cap | $678m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |